• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Decoding 4 Analyst Evaluations For Ashland

    4/11/24 11:01:38 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary
    Get the next $ASH alert in real time by email

    In the last three months, 4 analysts have published ratings on Ashland (NYSE:ASH), offering a diverse range of perspectives from bullish to bearish.

    The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 1 1 1 1 0
    Last 30D 0 1 0 0 0
    1M Ago 1 0 0 0 0
    2M Ago 0 0 0 0 0
    3M Ago 0 0 1 1 0

    Analysts have set 12-month price targets for Ashland, revealing an average target of $106.5, a high estimate of $126.00, and a low estimate of $88.00. Observing a 21.71% increase, the current average has risen from the previous average price target of $87.50.

    price target chart

    Interpreting Analyst Ratings: A Closer Look

    An in-depth analysis of recent analyst actions unveils how financial experts perceive Ashland. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

    Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
    Michael Sison Wells Fargo Raises Overweight $112.00 $100.00
    Laurence Alexander Jefferies Raises Buy $126.00 $100.00
    Jeffrey Zekauskas JP Morgan Raises Underweight $88.00 $70.00
    Michael Sison Wells Fargo Raises Equal-Weight $100.00 $80.00

    Key Insights:

    • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ashland. This offers insight into analysts' perspectives on the current state of the company.
    • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ashland compared to the broader market.
    • Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ashland's stock. This comparison reveals trends in analysts' expectations over time.

    Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ashland's market standing. Stay informed and make data-driven decisions with our Ratings Table.

    Stay up to date on Ashland analyst ratings.

    All You Need to Know About Ashland

    Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. Ashland includes only U.S. and Canada in its North America designation and includes Europe, the Middle East and Africa in its Europe designation.

    Ashland's Financial Performance

    Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

    Negative Revenue Trend: Examining Ashland's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -9.9% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.

    Net Margin: Ashland's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.5% net margin, the company effectively manages costs and achieves strong profitability.

    Return on Equity (ROE): Ashland's ROE excels beyond industry benchmarks, reaching 0.85%. This signifies robust financial management and efficient use of shareholder equity capital.

    Return on Assets (ROA): Ashland's ROA stands out, surpassing industry averages. With an impressive ROA of 0.44%, the company demonstrates effective utilization of assets and strong financial performance.

    Debt Management: Ashland's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.48.

    The Significance of Analyst Ratings Explained

    Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

    Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASH

    DatePrice TargetRatingAnalyst
    12/15/2025$71.00Market Perform → Outperform
    BMO Capital Markets
    9/8/2025$60.00Equal-Weight
    Morgan Stanley
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    3/26/2025$68.00 → $71.00Neutral → Overweight
    Analyst
    3/5/2025Buy → Neutral
    Seaport Research Partners
    8/8/2024$90.00 → $89.00Underweight → Neutral
    JP Morgan
    4/11/2024$100.00 → $112.00Equal Weight → Overweight
    Wells Fargo
    3/14/2024$100.00 → $126.00Hold → Buy
    Jefferies
    More analyst ratings

    $ASH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Harrison Suzan F.

    4 - ASHLAND INC. (0001674862) (Issuer)

    1/22/26 4:30:10 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Director Kulkarni Ashish K converted options into 2,113 shares (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    1/22/26 4:30:05 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 4 filed by Director Bishop Steven D

    4 - ASHLAND INC. (0001674862) (Issuer)

    1/21/26 6:00:19 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ashland reports first quarter fiscal 2026 results and narrows full-year outlook

    Sales of $386 million, down five percent from the prior-year quarterPreviously announced Avoca divestiture reduced overall sales by approximately $10 million or two percent versus the prior-year quarter; excluding the Avoca divestiture, sales declined three percentLoss from continuing operations of $14 million, or $(0.30) per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $12 million, or $0.26 per diluted shareNet loss of $12 million, or $(0.26) per diluted shareAdjusted EBITDA of $58 million, down five percent from the prior-year quarter, with the Avoca divestiture contributing to a two percent or $1 million decline; excluding the Avoca

    2/2/26 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Univar Solutions and Ashland Forge Exclusive Partnership for Cellulose Ethers in Food and Beverage Sector Throughout EMEA

    Expanding access in EMEA markets to meet rising demand for functional ingredients and drive innovation in food and beverage applications ESSEN, Germany, Jan. 27, 2026 /PRNewswire/ -- Univar Solutions B.V., a subsidiary of Univar Solutions LLC ("Univar Solutions" or "The Company"), a leading global solutions provider of specialty ingredients and chemicals, today announced an exclusive distribution partnership between their Foodology by Univar Solutions business and Ashland Inc. (NYSE:ASH). Ashland is a global, consumer-focused additives and specialty ingredients company recognized for its leading cellulose ether derivatives and polyvinylpolypyrrolidone (PVPP). Beginning January 1, 2026, this

    1/27/26 7:02:00 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland sets date for first-quarter fiscal 2026 earnings release and conference call webcast

    WILMINGTON, Del., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its first-quarter fiscal 2026 earnings release at approximately 5 p.m. ET on Monday, February 2, 2026. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Tuesday, February 3. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, senior vice president, and chief fina

    1/20/26 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    SEC Filings

    View All

    SEC Form 10-Q filed by Ashland Inc.

    10-Q - ASHLAND INC. (0001674862) (Filer)

    2/3/26 1:50:25 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASHLAND INC. (0001674862) (Filer)

    2/2/26 5:11:11 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ASHLAND INC. (0001674862) (Filer)

    1/27/26 4:30:25 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ashland upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Ashland from Market Perform to Outperform and set a new price target of $71.00

    12/15/25 8:56:16 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Morgan Stanley initiated coverage on Ashland with a new price target

    Morgan Stanley initiated coverage of Ashland with a rating of Equal-Weight and set a new price target of $60.00

    9/8/25 8:48:38 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland downgraded by Wells Fargo

    Wells Fargo downgraded Ashland from Overweight to Equal Weight

    5/1/25 3:02:01 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    2/3/25 4:30:05 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SVP and GM, Life Sciences Assis Alessandra Faccin bought $201,600 worth of shares (3,150 units at $64.00) (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    2/3/25 4:30:03 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Financials

    Live finance-specific insights

    View All

    Ashland reports first quarter fiscal 2026 results and narrows full-year outlook

    Sales of $386 million, down five percent from the prior-year quarterPreviously announced Avoca divestiture reduced overall sales by approximately $10 million or two percent versus the prior-year quarter; excluding the Avoca divestiture, sales declined three percentLoss from continuing operations of $14 million, or $(0.30) per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $12 million, or $0.26 per diluted shareNet loss of $12 million, or $(0.26) per diluted shareAdjusted EBITDA of $58 million, down five percent from the prior-year quarter, with the Avoca divestiture contributing to a two percent or $1 million decline; excluding the Avoca

    2/2/26 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland sets date for first-quarter fiscal 2026 earnings release and conference call webcast

    WILMINGTON, Del., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its first-quarter fiscal 2026 earnings release at approximately 5 p.m. ET on Monday, February 2, 2026. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Tuesday, February 3. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, senior vice president, and chief fina

    1/20/26 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland board authorizes quarterly dividend

    WILMINGTON, Del., Jan. 19, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock. The dividend will be payable on March 15, 2026, to stockholders of record at the close of business on March 1, 2026. As of December 31, 2025, there were 45,762,391 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coat

    1/19/26 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ashland Inc.

    SC 13G - ASHLAND INC. (0001674862) (Subject)

    11/12/24 11:54:03 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Ashland Inc.

    SC 13G/A - ASHLAND INC. (0001674862) (Subject)

    7/10/24 1:14:41 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

    SC 13D/A - ASHLAND INC. (0001674862) (Subject)

    4/25/24 4:15:12 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Leadership Updates

    Live Leadership Updates

    View All

    Ashland announces executive leadership changes

    WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan

    5/5/25 5:00:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

    Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu

    9/3/24 7:00:00 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

    Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio

    9/3/24 7:00:00 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary